Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes.
Amin H NassarTalal El ZarifAhmed Bilal KhalidSerena RahmeCaiwei ZhongLucia KwakMarita SalameElias Bou FarhatDory FreemanEdward El-AmArjun RavishankarBachar AhmadFrank Aboubakar NanaDavid KaldasAbdul Rafeh NaqashElad SharonNicole R LeBoeufAlessio CortelliniAndrea MalgeriShruti GuptaAhmad Al-HaderJeffrey A SparksJenny LinnoilaOle-Petter R HamnvikTarek H MouhieddineThomas U MarronKaushal ParikhRana R McKayThomas DillingToni K ChoueiriElio AdibElie NajemSo Yeon KimGuru P SonpavdePublished in: Journal for immunotherapy of cancer (2024)
Exacerbations of pre-existing PNS occurred in 29% of patients treated with ICIs and both exacerbations and de novo PNS occur early in the ICI course. TrAE from ICIs were similar between patients with and without PNS. Our data suggest that pre-existing PNS should not preclude consideration of ICI therapy although patients may not derive the same clinical benefit compared with patients without PNS.